Design and Synthesis of Some New Quinoxaline-1,2,4-Oxadiazole-Amide Conjugates as EGFR Targeting Agents and ADMET Studies

[1]  N. Thirukovela,et al.  One-Pot Synthesis of Some New Phthalazine-Piperazine-1,2,4-Oxadiazole Hybrids: Anticancer Evaluation, Molecular Docking and ADMET Studies , 2022, Polycyclic Aromatic Compounds.

[2]  T. Rungrotmongkol,et al.  Quinoxalinones as A Novel Inhibitor Scaffold for EGFR (L858R/T790M/C797S) Tyrosine Kinase: Molecular Docking, Biological Evaluations, and Computational Insights , 2022, Molecules.

[3]  Mohammad Mahboob Alam,et al.  Benzimidazole‐1,3,4‐Oxadiazole Hybrids: Synthesis, Anticancer Evaluation, Docking and DFT Studies , 2022, ChemistrySelect.

[4]  Thikryat Neamatallah,et al.  Synthesis, Biological Evaluation, and Molecular Docking of New Benzimidazole-1,2,3-Triazole Hybrids as Antibacterial and Antitumor Agents , 2022, Polycyclic Aromatic Compounds.

[5]  M. Alfaifi,et al.  Naproxen Based 1,3,4-Oxadiazole Derivatives as EGFR Inhibitors: Design, Synthesis, Anticancer, and Computational Studies , 2021, Pharmaceuticals.

[6]  Mai E. Shoman,et al.  Molecular hybrids: A five-year survey on structures of multiple targeted hybrids of protein kinase inhibitors for cancer therapy. , 2021, European journal of medicinal chemistry.

[7]  F. Mohamed,et al.  Design, synthesis, and biological evaluation of novel EGFR inhibitors containing 5-chloro-3-hydroxymethyl-indole-2-carboxamide scaffold with apoptotic antiproliferative activity. , 2021, Bioorganic chemistry.

[8]  H. Salah,et al.  Synthesis, EGFR-TK inhibition and anticancer activity of new quinoxaline derivatives , 2020 .

[9]  A. Foroumadi,et al.  A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. , 2020, Bioorganic chemistry.

[10]  Syed Nazreen,et al.  Synthesis, characterization and cytotoxic study of 2-hydroxy benzothiazole incorporated 1,3,4-oxadiazole derivatives , 2020, Egyptian Journal of Chemistry.

[11]  M. Gabr,et al.  Synthesis, molecular modeling and biological evaluation of new pyrazolo[3,4-b]pyridine analogs as potential antimicrobial, antiquorum-sensing and anticancer agents. , 2019, Bioorganic chemistry.

[12]  Simona Musella,et al.  New 1,2,4-Oxadiazole Nortopsentin Derivatives with Cytotoxic Activity , 2019, Marine drugs.

[13]  D. Mahadevan,et al.  A comprehensive review of protein kinase inhibitors for cancer therapy , 2018, Expert review of anticancer therapy.

[14]  Hany E. A. Ahmed,et al.  Design, synthesis, molecular docking of new lipophilic acetamide derivatives affording potential anticancer and antimicrobial agents. , 2018, Bioorganic chemistry.

[15]  Hany E. A. Ahmed,et al.  Design, Synthesis and Cytotoxic Evaluation of Novel Chalcone Derivatives Bearing Triazolo[4,3-a]-quinoxaline Moieties as Potent Anticancer Agents with Dual EGFR Kinase and Tubulin Polymerization Inhibitory Effects , 2017, Molecules.

[16]  T. Owa,et al.  Selective degradation of splicing factor CAPERα by anticancer sulfonamides. , 2017, Nature chemical biology.

[17]  Olivier Michielin,et al.  SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules , 2017, Scientific Reports.

[18]  T. Regad.  Targeting RTK Signaling Pathways in Cancer , 2015, Cancers.

[19]  Douglas E. V. Pires,et al.  pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures , 2015, Journal of medicinal chemistry.

[20]  H. Abdel‐Aziz,et al.  Design, synthesis and in vitro antitumor activity of novel N-substituted-4-phenyl/benzylphthalazin-1-ones. , 2015, European journal of medicinal chemistry.

[21]  I. Konstantinov,et al.  Antiproliferative 4-(1,2,4-oxadiazol-5-yl)piperidine-1-carboxamides, a new tubulin inhibitor chemotype. , 2014, Bioorganic & medicinal chemistry letters.

[22]  E. Rajanarendar,et al.  Design, synthesis, in vitro antimicrobial and anticancer activity of novel methylenebis-isoxazolo[4,5-b]azepines derivatives. , 2012, European journal of medicinal chemistry.

[23]  A. Plowright,et al.  Oxadiazoles in medicinal chemistry. , 2012, Journal of medicinal chemistry.

[24]  K. Shah,et al.  Synthesis of novel 1,2,4-oxadiazoles and analogues as potential anticancer agents. , 2011, European journal of medicinal chemistry.

[25]  L. Gediya,et al.  Promise and challenges in drug discovery and development of hybrid anticancer drugs , 2009, Expert opinion on drug discovery.

[26]  M. Ratain,et al.  A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours. , 2008, European journal of cancer.

[27]  Giovanni Sorba,et al.  Click chemistry reactions in medicinal chemistry: Applications of the 1,3‐dipolar cycloaddition between azides and alkynes , 2008, Medicinal research reviews.

[28]  G. Tortora,et al.  Rational bases for the development of EGFR inhibitors for cancer treatment. , 2007, The international journal of biochemistry & cell biology.

[29]  M. Verdonk,et al.  A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. , 2007, Current topics in medicinal chemistry.

[30]  J. W. Bode.  Emerging methods in amide- and peptide-bond formation. , 2006, Current opinion in drug discovery & development.

[31]  C. Montalbetti,et al.  Amide bond formation and peptide coupling , 2005 .

[32]  L. Qiu,et al.  Discovery and structure-activity relationship of 3-aryl-5-aryl-1,2,4-oxadiazoles as a new series of apoptosis inducers and potential anticancer agents. , 2005, Journal of medicinal chemistry.

[33]  B. Higgins,et al.  Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models , 2004, Anti-cancer drugs.

[34]  Hanlin Gao,et al.  Chloroquinoxaline Sulfonamide (NSC 339004) Is a Topoisomerase IIα/β Poison , 2000 .

[35]  Hanlin Gao,et al.  XK469, a selective topoisomerase IIbeta poison. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[36]  A. Chamberlin,et al.  Chemical Synthesis of Natural Product Peptides: Coupling Methods for the Incorporation of Noncoded Amino Acids into Peptides. , 1997, Chemical reviews.

[37]  A. Ghose,et al.  A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. , 1999, Journal of combinatorial chemistry.